Brokerages Set Twist Bioscience Co. (NASDAQ:TWST) Price Target at $54.40

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $54.40.

Several equities analysts have commented on the stock. Robert W. Baird raised their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Wolfe Research started coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the company an “overweight” rating in a research report on Monday, February 3rd. Finally, TD Cowen reiterated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th.

Insiders Place Their Bets

In other news, CFO Adam Laponis sold 5,886 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the sale, the chief financial officer now owns 110,096 shares in the company, valued at approximately $4,762,752.96. This represents a 5.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Emily M. Leproust sold 2,216 shares of the business’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $116,783.20. Following the completion of the transaction, the chief executive officer now owns 674,718 shares in the company, valued at $35,557,638.60. This trade represents a 0.33 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,180 shares of company stock valued at $1,821,971. 3.01% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Signaturefd LLC grew its position in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares during the last quarter. International Assets Investment Management LLC lifted its position in Twist Bioscience by 4,418.3% in the third quarter. International Assets Investment Management LLC now owns 4,925 shares of the company’s stock valued at $223,000 after purchasing an additional 4,816 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Twist Bioscience by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,268 shares of the company’s stock worth $509,000 after buying an additional 4,427 shares in the last quarter. Finally, SteelPeak Wealth LLC acquired a new stake in shares of Twist Bioscience in the 3rd quarter valued at approximately $416,000.

Twist Bioscience Stock Down 4.4 %

NASDAQ:TWST opened at $37.11 on Thursday. Twist Bioscience has a 52 week low of $27.41 and a 52 week high of $60.90. The stock’s fifty day moving average is $47.45 and its two-hundred day moving average is $45.63. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -10.98 and a beta of 1.87. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same period last year, the business posted ($0.75) EPS. Research analysts anticipate that Twist Bioscience will post -2.12 EPS for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.